Descriptive Summary
James Arly Nelson
Howard Earle Skipper
James Arly Nelson collection of Howard Earle Skipper manuscripts and other materials,
1962-1993
Materials are written in English
HRC Skipper Howard
6.3 linear feet(264 manuscripts, 2 letters)
Historical Resources Center, Research Medical Library,The University of Texas M. D. Anderson Cancer Center
Collection consists mainly of Howard Earle Skipper's cancer booklets published by the Scientific Research Institute of Birmingham, Alabama. The collection also contains other materials from James Arly Nelson's personal collection.
Biographical Note
Howard Earle Skipper was born in 1915 in Avon Park, Florida to Chesley Allen and Estelle Wiggins Skipper. He attended the University of Florida and earned a Bachelor of Science degree in 1938 and a Master’s of Science Degree in 1939. He received a Doctor of Philosophy degree in Biochemistry and Nutrition in 1941. From 1941-1945, he served in the U.S. Army’s Chemical Warfare Service and retired with the rank of Lt. Colonial. In 1946, he established the Cancer Chemotherapy Research Program at the Southern Research Institute (SRI). He became head of the SRI’s Organic and Biochemical Division in 1949, Vice President and Director of the Kettering-Meyer Laboratory in 1964, and President in 1974. While at the SRI, he wrote and published over 200 scientific articles and booklets, dubbed “Skipper Booklets” on cancer research. He also served as Professor of Experimental Pathology at the School of Medicine and Professor of Investigative Medicine, Department of Medicine at the University of Alabama in Birmingham. His awards include an Albert Lasker Award for Basic Medical Research in 1975 and an Ernst Bertner Memorial Award from the M. D. Anderson Hospital and Tumor Institute of the University of Texas System Cancer Center in 1976.
In 1940, he married Margaret T. Edwards and remained married until her death in 1984; the couple had two children. Dr. Howard Earle Skipper died in Mountain Brook, Alabama on January 2, 2006 at the age of 90.
Scope and Content Note
The collections consists mainly of over 200 of Howard Earle Skipper’s “Skipper’s Booklets” published by the Southern Research Institute from 1974 to 1989. Other materials in the collection include other manuscripts, research articles, publications, and correspondence collected by James Arly Nelson Nelson from 1962-1993.
Restrictions on Access
This collection contains no restrictions
Preferred Citation
James Arly Nelson collection of Howard Earle Skipper manuscripts and other materials, 1962-1993, Research Medical Library, The University of Texas M. D. Anderson Cancer Center.
Restrictions on Use
All requests for copying of materials must be submitted to the Historical Resources Center in writing for approval. All reproductions will be handled by HRC staff
Authorization to publish, quote, or reproduce must be obtained in writing by the Historical Resources Center
Processing Information
This collection was processed by Jose Javier Franco Garza, Archivist, in August 2010
Provenance
This collection was donated to the Historical Resources Center at MD Anderson's Research Medical Library by James Arly Nelson.
Detailed Description of the Records
1974
1
1
Toxicity and Rate of Host Recovery: Cyclophosphamide, Adriamycin, Cyclophosphamide + Adriamycin (Simultaneous), Cyclophosphamide--Adriamycin, and Adriamycin--Cyclophosphamide,
January
Booklet
1
2
IN VITRO Response of Log Phace and Resting Tumor Cell Populations to Adriamycin and Daunomycin,
January
Booklet
1
3
IN VIVO Response of Tumors to Cyclophosphamide, Adriamycin, and the Combination,
January
Booklet
1
4
Combination Chemotherapy and Combination Therapy,
February
Booklet
1
5
Combination Chemotherapy and Combination Therapy,
March
Booklet
1
6
Combination Chemotherapy and Combination Therapy,
March
Booklet
1
7
Combination Chemotherapy and Combination Therapy,
April
Booklet
1
8.1
Combination Chemotherapy and Combination Therapy,
April
Booklet
1
8.2
Combination Chemotherapy and Combination Therapy,
May
Booklet
1
8.3
Combination Chemotherapy and Combination Therapy,
June
Booklet
1
8.4
Combination Chemotherapy and Combination Therapy,
July
Booklet
1
9
Combination Chemotherapy and Combination Therapy,
July
Booklet
1
10
Combination Chemotherapy and Combination Therapy,
August
Booklet
1
11
Combination Chemotherapy and Combination Therapy,
September
Booklet
1
12
Therapy and Combination Therapy,
October
Booklet
1976
2
1
Phase I Studies on the Carcinogenic Activity of Anticancer Drugs in Mice and Rats,
February
Booklet
2
2
Results of Phase I Carcinogenic Assays on Drug Combinations,
March
Booklet
2
3
Are There Ways of Administering Anticancer Drugs (e.g., After Surgery) That will Retain Maximum Therapeutic Benefit and at the Same Time Minimize Potential New Tumor Risk in Individuals Who Are Cured?,
April
Booklet
2
4
Tumor Type Distributions Observed in Untreated Mice and Rats Compared to Those Observed in Companion Animals Treated Chronically with Anticancer Drugs,
May
Booklet
2
5
The Lewis Lung Carcinoma System,
July
Booklet
2
6
Missing,
???
Booklet
2
7
L1210 Leukemia; Response to Cyclophosphamide,
October
Booklet
2
8
L1210 Leukemia; Response to BCNU,
November
Booklet
2
9
L1210 Leukemia; Response to CCNU and Methyl CCNU,
November
Booklet
2
10
L1210 Leukemai; Response to ARA-C /AND/ A Pilot Study of Rate and Response Phenomena Associated With Remission Induction of AML with ARA-C Alone,
December
Booklet
1977
2
1
Murine Leukemias; Response to Methotrexate and Methotrexate--CF /AND/ Theoretical Considerations of Some Problems Presently Faced in Use of Methotrexate in Treatment of Human Cancers,
February
Booklet
2
2
L1210 Leukemia; Response to 6-Mercaptopurine, 6-Thioguanine, and Combinations Including the Latter (Simultaneous ARA-C + 6-TG and ARA-C + 6-TG-Cyclophosphamide + BCNU,
March
Booklet
2
3
Intergration of Information on Dose Response and Tumor Cell Repolulation Rate in Design of Chemotherapeutic Trials,
April
Booklet
2
4
Reexamination of Therapeutic Trial Results Obtained with Cyclophosphamide in a Hamster Plasmacytoma (PLA-1),
June
Booklet
2
5
5-Flourouracil; Response of Murine Leukemias at Different Stages to a Variety of Dosage Regimens,
June
Booklet
2
6
Adjuvant Chemotherapy,
June
Booklet
3
7
Combination Chemotherapy; Advanced and Very Advanced IV Inoculated L1210 Leukemia,
July
Booklet
3
8
Response of Transplanted and Spontaneous Murine Leukemias to Vincristine and Vinblastine,
July
Booklet
3
9
Adriamycin and Actinomycin D; Response of Murine Leukemias /AND/ Observations on Cross-Resistance and Lack of Cross-Resistance in Sublines of P388 Leukemia Selected By Vincristine, Adriamycin, and Actinomycin D,
August
Booklet
3
10
On the Rate of Selection of Resistant Neoplastic Cells by Alkylating Agents, and the Two Different Patterns of Cross-Resistance Observed in Such Tumor Cell Populations,
September
Booklet
3
11
Response of Ridgeway Osteogenic Sarcoma (ROS) at Different Stages to a Variety of Drugs Given According to Different Schedules,
October
Booklet
3
12
Implication of Data on Solid Tumor Mass Behavior During and After Treatment; Ridgway Osteogenic Sarcoma,
October
Booklet
3
13
Combination Chemotherapy; Ridgway Osteogenic Sarcoma; Actinomycin D + Cyclophosphamide,
November
Booklet
3
14
Combination Chemotherapy; Ridgway Osteogenic Sarcoma; Cyclophosphamide Plus 6-Mercaptopurine,
November
Booklet
3
15
Combination Chemotherapy; Ridgway Osteogenic Sarcoma; Cyclophosphamide Plus L-Pam,
December
Booklet
3
16
Combination Chemotherapy; Ridgway Osteogenic Sarcoma; Two-Drug Combinations Comprising One Highly Effective and One Moderately Effective Agent: L-PAM + 6-MP, L-PAM + 5-FU Cyclophosphamide + 5-FU,
December
Booklet
3
17
Surgery -- Chemotherapy,
December
Booklet
1978
3
1
Experimental Therapeutics and Ancillary Research With Basic and Applied Goals (Cancer Treatment),
January
Booklet
3
2
"Faceting Must Be Difficult!" "How Do You Do It?",
February
Booklet
3
3
Reasons For Success and Failure in Treatment of Murine Leukemias With the Drugs Now Employed In Treating Human All and AML,
March
Booklet
3
4
On the Rate of Selection of Leukemia Cell Polulations With Varying Degrees of Resistance to (a) Multidrug Combinations and (b) The Indidvidual Drugs That Comprise the Combinations,
April
Booklet
3
5
Is Overgrowth of Drug-Resistant Neoplastic Cells a Major Cause of Chemotherapeutic Failure at the Human Level?,
April
Booklet
4
6
Breast Cancer in Premenopausal and Postmenopausal Women; Surgery Alone and Surgery-Chemotherapy; A Brief Consideration of Some Specific Questions,
May
Booklet
4
7
Cancer Chemotherapy; A Review of Experience in Treatment Design with Emphasis on (1) Critical Variables, (2)Reasons for Success and Failure, and (3)Opportunities for Improvement in the Foreseeable Future,
June
Booklet
4
8
On Further Testing of a Stratagy Aimed at Reducing Treatment Failures Due to Overgrowth of Drug-Resistant Neoplastic Cells (P-388 Leukemia),
July
Booklet
4
9
Some Pitfalls in Design of Combination Chemotherapy; Experimental Observations,
August
Booklet
4
10
Missing,
???
Booklet
4
11
On Reducing Treatment Failures Due to Overgrowth of Specifically and Permanently Drug-Resistant Neoplastic Cells (Murine Leukemias),
September
Booklet
4
12
Idealized Hypothetical Illustrations of the Effects of Specifically Drug-Resistant Leukemia Cells on End-Results Achievable with Chemotherapy,
November
Booklet
4
12-A
Is Overgrowth of Drug-Resistant Breast Cancer Cells One of the Causes of Chemotherapeutic Failure When Drugs are Employed After Mastectomy?,
November
Booklet
1979
4
1
Experimental Therapeutics and Ancillary Research With Basic and Applied Goals (Cancer Treatment),
January
Booklet
4
2
A Review and More Quantitative Analysis of the Results of Many Internally Controlled Combination Chemotherapy Trials Carried Out Over the Past Fifteen Years (L1210 Leukemia and P388 Leukemia),
February
Booklet
4
3
Ridgeay Osteogenic Sarcoma; Response at Different Stages to Surgery, Single Drugs, Combinations of Drugs and Surgery-Chemotherapy,
March
Booklet
4
4
Historic Milestones in Cancer Biology; a Few that are Important in Cancer Treatment (Revisited),
April
Booklet
4
5
Lewis Lung Carcinoma; Resonse to Surgery, Chemotherapy, and Surgery-Chemotherapy,
May
Booklet
4
6
Colon Tumor 26; Response to Surgery, Chemotherapy, and Surgery-Chemotherapy,
May
Booklet
5
7
Comparative Trials Showing the Response of Animals Bearing Mammary Tumors 16/C and Line 44 to Chemotherapy, Surgery, and Surgery Plus Chemotherapy,
June
Booklet
5
8
On the Selection and Overgrowth of Drug-Resistant Leukemia Cells Outside and Within the Blood-Brain Barrier-and Their Passage in Both Directions,
June
Booklet
5
9
Concurrent Comparisons of some 2-, 3-, and 4-Drug Combinations Delivered Simultaneously and Sequentially (L1210 and P388 Leukemia Systems),
July
Booklet
5
10
Some Thoughts Regarding the Modes of Action of Drugs on Cells and on Application of Available Pharmacokinetic Data (Anticancer Drugs),
September
Booklet
5
11
On Application of Pharmacokinetic Information in Planning and Interpretation of Therapeutic Trials (Anticancer Drugs),
October
Booklet
5
12
Repopulation Rates of Breast Cancer Cells After Mastectomy (Judged From Breakpoints in Remission-Duration Curves),
December
Booklet
1980
5
1
Summaries of Data Examined in Booklets Written in 1979,
January
Booklet
5
2
Response of Advanced Breast Cancer to CMF (Cyclophosphamide + Methotrexate + 5-Flourouracil),
January
Booklet
5
3
On the Effectiveness of Relatively Low Concentrations of ARA-C Achieved in the Brain on Leukemia Cells in the Brain,
February
Booklet
5
4
Breast Cancer Treated by Means of Mastectomy and Mastectomy Followed by 12 or 16 Cycles of CMF,
February
Booklet
5
5
Arabinosylcytosine (ARA-C) Pharmacokinetic Data; Dose-Response and Time-Action Response; Toxicity Data; Data on the Rate of Neoplastic Cells and Therapeutic Resonse Results,
April
Booklet
5
6
On the Mode and Rate of Selection of Drug-Resistant Cancer Cell Populations; and Some Updating of Information on Cross-Resistance and Lack of Cross-Resistance with Emphasis on Switching Drugs at or Near the Nadir,
May
Booklet
5
7
Second Remissions with the Same Drug(s) That Provided an Initial Remission Induction,
May
Booklet
5
8
Some Views or Concepts or Hypotheses or Theories That Seem Useful in the Theory and/or Practice of Cancer Treatment,
June
Booklet
5
9
Some Thoughts Regarding a Recent Publication by Goldie and Coldman Entitled: "A Mathamatic Model for Relating the Drug Sensitivity of Tumors to Their Spontaneous Mutation Rate",
June
Booklet
5
10
Additional Thoughts on the Model of Goldie and Coldman,
July
Booklet
5
11
What is the Best Stratagy for Treating Animals Bearing Varying Burdens and Mixes of Sensitive, Singly Drug-Resistant and Doubly Resistant Neoplastic Cells?,
July
Booklet
5
12
How Can One Anticipate when the Median Nadir in Surviving Tumor Cells Will Be Achieved by Some Remission-Inducing Chemotherapy?,
July
Booklet
6
13
On the Remarkable Progress that Has Been Made in Treatment of Hodgkin's Disease,
August
Booklet
6
14
On Treatment of Non-Hodgkin's Lymphomas,
September
Booklet
6
15
Reexamination of the Problem of Singly, Doubly, and Multidrug-Resistant Neoplastic Cells in Cancer Treatment,
October
Booklet
6
16
Some Uninhibited Thoughts on the Heterpgeneity of Neoplastic Cells and Implications in Cancer Treatment,
October
Booklet
6
17
Cross-Resistance and Lack of Cross-Resistance Between Anticancer Drugs of the Same and Different Classes,
October
Booklet
6
18
Thoughts on Points Emphasized by Holland in a Recent Essay Entitled "Chemotherapy of Gigacytomas: The Treatment and Curability of 'solid' Tumors with Drugs",
November
Booklet
6
19
On the LACK of Cross-Resistance of a cis-DDPt-Resistant Subline of Leukemia Cells to Nitrosoureas and other Alkylating Agents,
December
Booklet
6
20
Continuing Analyses of Primary Causes of Chemotherapeutic Failure,
December
Booklet
1981
6
1
Summaries of Data Examined in Booklets written in 1980,
January
Booklet
6
2
Melanoma; Regrowth Rates in Surgical Failures and Estimates of the Residual Tumor Cell Burden Immediately After Surgery,
January
Booklet
6
3
What May Happen if an Initial Chemotherapeutic Regimen is Continued Too Long Before Switching, or Beginning Alternation of Non-Cross-Resistant Drugs?,
February
Booklet
6
4
Growth and Regrowth Rates of Human Cancers; Preliminary Bracketing Studies,
March
Booklet
6
5
Some Thoughts on Screening for New Anticancer Drugs: Past, Present, and Future,
April
Booklet
6
6
On the Guy Who WritesThese Things Referred to as Booklets,
April
Booklet
6
7
What is Cancer? How Do Cancer Cells Differ From Their Normal Cells of Origin? Why do Different Cancers (And Even Individual Tumors of the Same Histologic Type) Often Respond Quite Differently to Drugs Which Inhibit DNA Replication or Function, or Inhibit Mitosis or Affect Hormonal Balance?,
April
Booklet
6
8
Growth Rates of the Progeny of Single Leukemia Cells. Do "Slow" Cells Give Rise to Progeny with More Rapid Growth Rates,
April
Booklet
6
9
Computer Simulations of Chemotherapeutic End-Results I,
May
Booklet
6
10
Computer Simulations of Chemotherapeutic End-Results II,
May
Booklet
7
11
Computer Simulations of Chemotherapeutic End-Results III,
June
Booklet
7
12
Computer Simulations of Chemotherapeutic End-Results IV,
July
Booklet
7
13
Response of M5076 Solid Tumors to Different Doses and Numbers of Doses of Methyl CCNU; Reasons for Recurrence After PR's and CR's,
July
Booklet
7
14
Melanoma; Prognostic Features as They Relate to the Residual Tumor Cell Burden Immediately After Surgery in Surgical Failures,
August
Booklet
7
15
Internally Controlled Trials Comparing the Effectiveness of a Two-drug Combination Delivered Simultaneously, in an Alternating Manner, and Sequentially (Palmo-Ara-C Plus Ctclophosphamide; L1210 Leukemia,
August
Booklet
7
16
Some Retrospective Simulations of the Response of All in Children to Single Drugs and Combinations of Drugs,
August
Booklet
7
17
Single-Drug Treatment and a Two-Drug Combination Delivered in Different Ways: Colon Adenocarcinoma 36\,
September
Booklet
7
18
Some Analyses and Trial-and-Error Simulations of the Response of Breast Cancer to Surgery Chemotherapy, and Surgery Plus Chemotherapy,
September
Booklet
7
19
Interpretations of a Trial Designed to Gain Basic Information Regarding the Influence of (1) The Initial Leukemia Cell Burden and Mix, (2) The L1210/0 Leukemia Cell Kill Per Dose of Cyclophosphamide, and (3) The Schedule on the Cure Rate and the Surviving Leukemia Cell Burden and Mix in Treatment Failures,
October
Booklet
7
20
Some Hypotheses or Concepts or Views that Seem Useful in the Theory and Practice of Cancer Treatment,
October
Booklet
7
21
Part 1; P388 Leukemia,
November
Booklet
7
22
Part II; L1210 Leukemia,
December
Booklet
7
23
Results and Interpretations of Trials in Which Animals Bearing Known Burdens and Mixes of Sensitive and Drug-Resistant Leukemia Cells Were Treated with Single Drug-Resistant Leukemia Cells Were Treated with Single Drugs and Two-Drug Combinations,
December
Booklet
1982
7
1
Summaries of Data Examined in Booklets written in 1981,
January
Booklet
7
2
Why Does Effective but Noncurative Chemotherapy Consistently Increase the Variance in the Survival Times of Treatment Failures,
January
Booklet
7
3
Some Additional Observations, Views, Concepts, and Theories that Seem Applicable in the Practice of Cancer Treatment,
February
Booklet
7
4
Some Thoughts on the Optimum Number of Drugs in Combination Chemotherapy and the Optimum Method(s) for Their Delivery,
February
Booklet
7
5
Variables Which Influence the Rate of Selection of Singly and Doubly Drug-Resistant Tumor Stem Cells,
March
Booklet
7
6
Why is it Sometimes Possible to Achieve Second Remissions with the Same Drug or Drugs That Provided an Earlier Remission?,
March
Booklet
8
7
Do "Slow" Leukemia Stem Cells That Survive A Single High Does of Cyclophosphamide Give Rise to Progeny with Longer than Average Doubling Times? Are Such Cells Notably Resistant to and LD10 Dose of Cyclophosphamide?,
March
Booklet
8
8
On the Origin of Singly and Doubly Drug-Resistant Neoplastic Cells: Cross-Resistance, Lack of Cross-Resistance, and Occasional Collateral Sensitivity; and Some Implications,
April
Booklet
8
9
Kinetics and Phenotypic Heterogeneity Revisited,
April
Booklet
8
10
Some Variables which Affect the Shapes of Survival Curves in Leukemic Animals,
April
Booklet
8
11
Comparisons of the Shapes of Survival Curves for Variously Treated Children with Acute Lymphocytic Leukemia (1956-1980) AND Those for Leukemic Animals where the Effects of Variables that Influence the Shapes of such Curves and Cure Rates are Known,
May
Booklet
8
12
Solid Tumors in Animals Treated with Surgery, Chemotherapy, or Surgery Plus Chemotherapy; Variables which Affect cure Rates and the Shapes and Slopes of Remission and Survival Curves (Part I),
June
Booklet
8
13
On Simulations of the Continually Changing Burden and Mix of Drug-Sensitive and Drug-Resistant Neoplastic Cells During Chemotherapy (Some Reasonable Estimates for Critical Variables),
July
Booklet
8
14
Solid Tumors in Animals Treated with Surgery, Chemotherapy, or Surgery Plus Chemotherapy; Variables which Affect cure Rates and the Shapes and Slopes of Remission and Survival Curves (Part II) Ridgway Osteogenic Sarcoma,
July
Booklet
8
15
Human Cancers; Shapes and Slopes of Remission and Survival Curves and Variables that Affect Them; PART I. Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Curkitt's Lymphoma and Diffuse Histiocytic Lymphoma,
July
Booklet
8
16
Human Cancers; Shapes and Slopes of Remission and Survival Curves and Variables that Affect Them; PART II. Hodgkin's Disease,
July
Booklet
8
17
Human Cancers; Shapes and Slopes of Remission and Survival Curves and Variables that Affect Them; PART III. Breast Cancer,
August
Booklet
8
18
Human Cancers; Shapes and Slopes of Remission and Survival Curves and Variables that Affect Them; PART IV. A Spectrum of Neoplastic Diseases,
September
Booklet
8
19
How Long May One Treat a Particular Neoplastic Disease with a Particular Chemotherapeutic Regimen Before That Regimen Will Have Achieved All the Benefit Possible? PART I,
October
Booklet
8
20
How Long May One Treat a Particular Neoplastic Disease with a Particular Chemotherapeutic Regimen Before That Regimen Will Have Achieved All the Benefit Possible? PART II,
October
Booklet
8
21
More on the Criteria for Optimum Delivery of Non-Cross-Resistant Anticancer Drugs,
November
Booklet
8
22
The Forty-Year-Old Mutation Theory of Luria and Delbruck and Its Pertinence to Cancer Chemotherapy,
December
Booklet
1983
8
1
Summaries of Data Examined in Booklets Written in 1982,
January
Booklet
8
2
On Delivery of Non-Cross-Resistant Combinations of Drugs in Treatment of Disseminated Breast Cancer. PART I,
January
Booklet
8
3
Mammary Adenocarcinoma 16/C; Remission Followed by Relapse During Continuing Undiminished Treatment With a Three-Drug Combination (CAF) Delivered Simultaneously,
February
Booklet
8
4
On Optimum Delivery of Combinations of Drugs (L1210 Leukemia System),
February
Booklet
9
5
An Attempt to Analyze and Interpret the Important Experiments of Schmid, Hutchison, Otter, and Stock (1976) in a Somewhat More Quantitative Manner,
March
Booklet
9
6
Influence of the Doses, Ks's, and Schedules of Both Drugs in Two-Drug Combinations on Remission Rates and Cure Rates; Ros System,
March
Booklet
9
7
P388 Leukemia; Response to 2-, 3-, And 4-Drug Combinations Delivered in Different Ways,
April
Booklet
9
8
Combination Chemotherapy; L1210 Leukemia System; Further Examinations of the Influence of Ks Sums and Ratios in Relation to Schedules and End-Results,
April
Booklet
9
9
Some Thoughts on Tumor Heterogeneity and Tumor Stem Cell Heterogeneity,
June
Booklet
9
10
Tumor Stem Cell Heterogeneity: Implications with Respect to Classification of Cancers by Chemotherapeutic Effect,
July
Booklet
9
11
Examples of Chemotherapeutic Regimens that Failed, the Reasons, and Changes Required for Improvement (L1210 Leukemia and Solid Tumors),
August
Booklet
9
12
Amoth the Last Enemies (Excepting Old Age): Disseminated Cancers,
August
Booklet
9
13
Some Thoughts on the Multidrug Protocol (L-2) Used byt the Memoria Sloan-Kettering Group in Treating Acute Lymphoblastic Leukemia,
September
Booklet
9
14
Some Thought on the Price-Hill Combination Chemotherapy Protocols for Treatment of Disseminated Malignancies,
October
Booklet
9
15
Examination of Additional Experimental Data in the Context of Chemotherapeutic Designs Advocated by Price and Hill,
November
Booklet
9
16
Relationships Between Tumor Stem Cell Heterogeneity and Responsiveness to Chemotherapy,
December
Booklet
1984
9
1
Summaries of Data Examined in Booklets Written in 1983,
January
Booklet
9
2
What Phenomena Are Primarily Responsible for Classifications of Cancers By Chemotherapeutic Effects?,
February
Booklet
9
3
Why Does the Relationship Between the Burden and Curability of a Particular Neoplasm by a Given Drug Remain Constant Over Years of Transplantation in Untreated Animals?,
February
Booklet
9
4
Are the Growth Rates of Drug-Resistant Neoplastic Cell Populations, Shortly After They Are Selected, Usually Similar to or Slower Than Those of the Parent Drug-Sensitive Neoplasm?,
March
Booklet
9
5
Growth Rates of Drug-Resistant Neoplasms During Relapse Compared With Growth Rates of the Parent Line in Untreated Control Animals,
March
Booklet
9
6
Growth Rates of Drug-Resistant Neoplasms During Relapse Compared With Growth Rates of the Parent Line in Untreated Control Animals,
April
Booklet
10
7
Growth Rates of Neoplasms Recurring During and After Temporarily Effective Chemotherapy Compared with Untreated Controls,
May
Booklet
10
8
Treatment Design Variables that Proved to Be Critical in Treating an Experimental Plasmacytoma (PLA-1) with Cyclophosphamide,
May
Booklet
10
9
Some Quantitative Relationships That Seem Critical in Cancer Chemotherapy,
June
Booklet
10
10
Analysis of Data that Seem to Document an Important Principle in Design of Combination Chemotherapy Regimens,
July
Booklet
10
11
Quantitative Analysis of the Influence of the Doses of Both Drugs in a 2-Drug Combination Delivered in an Alternating Manner--And Predictions of Required Doses When the Same Combination is Delivered in Other Ways.,
July
Booklet
10
12
Analysis of the Influence of the Doses of L-PAM and 6-MP When Given in Combination to Animals Bearing 2-3 Gram Ros Tumors,
August
Booklet
10
13
Analysis of Trials in Which Animals Bearing Ros Tumors Were Treated With Varying Doses of Both Drugs in 2-Drug Combinations,
August
Booklet
10
14
Influence of the Dose Intensity of C and A and F Delivered Weekly in a Simultanious Manner to Animals Bearing Mammary 16/C Tumors,
September
Booklet
10
15
A Look at the Influence of Dose Intensity of Adriamycin and 5-FU When a Combination of These Two Drugs was Delivered in Different Ways to Animals Bearing Mammary 16/C Tumors (Trial 1516-E1),
September
Booklet
10
16
Surgery + Chemotherapy; Some Quantitative Implications in Metastatic Neoplastic Disease,
October
Booklet
10
17
On Reasons for Variations in the Degree and Duration of Tumor Response Observed When Groups of Animals Bearing Similar Burdens of a Particular Neoplastic Disease Are Similarly Treated With Chemotherapy,
November
Booklet
10
18
Laboratory Models: Some Historical Perspective,
November
Booklet
10
19
Are Experimental Neoplasms Which Respond Temporarily, and Then Resume Growth During Treatment with a Combination of Non-Cross-Resistant Drugs, Resistant to All of the Individual Drugs in the Combination,
December
Booklet
1985
10
1
Summaries of Data Examined in Booklets Written in 1984,
January
Booklet
10
2
What Phenomena Are Primarily Responsible for Cancers being Classified as Responsive, Refractory, or Very Refractory to Chemotherapy?,
February
Booklet
11
3
Experimental Adjuvant Chemotherapy an Overview,
March
Booklet
11
4
On the Design of Redesign of Combination Chemotherapy Regimens to Be Used Alone or in an Adjuvant Setting; Goal: Reducing Failures Due to the Overgrowth of Specifically and Permanently Drug-Resistant Tumor Cells (T/R Cells),
May
Booklet
11
5
Idealized Simulations; on the Design or Redesign of Combination Chemotherapy Regimens to Be used Alone or in an Adjuvant Setting in Treating Disseminated Cancers,
June
Booklet
11
6
Some Thoughts on the Design and Redesign of Combination Chemotherapy Regimens for Treating Disseminated Breast Cancer,
July
Booklet
11
7
Influence of the Dose Intensity of C and A and F in Caf-Containing Regimens on the Response of an Experimental Neoplasm (Mammary Adenocarcinoma 16/C) and Advanced Breast Cancer in Women,
August
Booklet
11
8
Critical Variables in the Design of Combination Chemotherapy Regimens to Be Used Alone or in an Adjuvant Setting,
September
Booklet
11
9
A Review of Extensive Data on the Response of Different Experimental Neoplasms at Different Stages of Advancement to Varying Dose Intensities, Schedules, and Durations of Treatment With ARA-C, and a Slow Release Form of ARA-C,
November
Booklet
11
10
A Review of Extensive Data on the Response of Different Experimental Neoplasms at Different Stages of Advancement to Varying Dose Intensities, Schedules, and Durations of Treatment With Cyclophosphamide (CPA),
December
Booklet
1986
11
1
Summaries of Data Examined in Booklets Written in 1985,
January
Booklet
11
2
On Mathmatical Modeling of Critical Variables in Cancer Treatment (Goals: Better Understanding of the Past and Better Planning in the Future),
January
Booklet
11
3
Response of Different Experimental Neoplasms at Different Stages of Advancement to Varying Dose Intensities of Actinomycin D / AND/ The Influence of Systematic Variations in the Relative Dose Intensities (And Avg. RDI) of Actinomycin Dand Cyclophosphamide, in Alternating and Simultaneous Combination, on the Response of Animals Bearing 2-3 Gram Ros Tumors,
March
Booklet
11
4
Response of Different Experimental Neoplasms at Different Stages of Advancement to Different Dose Intensities of L-Pam (L-Phenylalanine Mustard) / AND / The Influence of Systematic Variation in the Relative Does Intensity of L-PAM and 6-Mercaptopurine in Alternating Combination on the Response of Animals Bearing 2-3 Gram Rost Tumors,
March
Booklet
11
5
Analysis of 42 Arms of Four Multiarmed Trials in Which Animals Bearing 2-3 Grams Ros Tumors Were Treated with a Simultaneous Combination of Cyclophosphamide + L-PAM with Systematic Variations of the Relative Dose Intensity of Each Drug, and the Average Relative Dose Intensity,
April
Booklet
11
6
Responsiveness of Different Experimental Neoplasms to 5-FU / AND / Analyses of Combination Chemotherapy Trials in Which Animals Bearing 2-3 grams Ros Tumors Were Treated with Alternating Combinations of Cyclophosphamide + 5-FU and L-PAM + 5-FU--With Variations in the Relative Dose Intensity of Each Drug and Average RDI's,
April
Booklet
11
7
Analysis of 42 Arms of Four Multiarmed Trials in Which Animals Bearing Different Burdens of L1210 Leukemia Cells Were Treated with 2-, 3-, and 4-Drug Combinations Delivered in Different Ways with Varying Dose Intensities of Each Drug and Varying Average Relative Does Intensities.,
May
Booklet
11
8
Analyses of Some Combination Chemotherapy Trials Carried Out in the P388 Leukemia System During the 1970s,
June
Booklet
12
9
Additional Analyses of Single Drug Treatment and Combination Chemotherapy Trials Carried Out in the L1210 Leukemia System During the 1960s and 1970s,
July
Booklet
12
10
Some Thoughts on Intrinsic Versus Acquired Drug Resistance in Cancers That Are Classified as Responsive, Refractory, or Very Refractory to Chemotherapy,
September
Booklet
12
11
Cross-Resistance and Lack of Cross-Resistance Between Anticancer Drugs: Concurrent Comparisons of the Response of the Parent Lines of Experimental Leukemias and Drug-Resistant Sublines Thereof to the Same Doses and Schedules of Various Classes of Drugs,
October
Booklet
12
12
Puzzling Questions Regarding a Transplantable Pancreatic Tumor (PANC 02) That Is Very Refractory to All Classes of Anti Cancer Drugs In Vivo,
November
Booklet
12
13
ARA-C and Cyclophosphamide; A Closer Look at the Influence of Dose Intensity and Treatment Duration on Host Toxicity and Therapeutic Response (Experimental Data),
December
Booklet
1987
12
1
Summaries of Data Examined in Booklets Written in 1986,
January
Booklet
12
2
BCNU, CCNU, and Methyl-CCNU; A Closer Look at the Influence of Dose Levels, Schedules, Dose Intensity, and Duration of Treatment on Both Toxicity and Therapeutic Response,
January
Booklet
12
3
Adriamycin; Influence of Dose Intensity and Duration of Treatment on Toxicity and the Therapeutic Response of P388 and L1210 Leukemias and Mammary Adenocarcinoma 16/C,
February
Booklet
12
4
Common Dose and Schedule Variables; Units, Combined Units, Relations, Effects on Toxicity, and Therapeutic Response, Etc., Etc., Etc.,
February
Booklet
12
5
Methotrexate; Influence of the Dose Intensity and the Duration of Treatment on Toxicity and the Therapeutic Response of Murine Leukemias,
February
Booklet
12
6
6-Thioguanine; Influence of Dose Intensity and Duration of Treatment on Toxicity and the Therapeutic Response of an Experimental Leukemia,
February
Booklet
12
7
Vincristine; Influence of Dose Intensity and Duration of Treatment on Toxicity and Therapeutic Response,
March
Booklet
12
8
5-Fluorouracil; Influence of Dose Intensity and Duration of Treatment on Toxicity and Therapeutic Response,
March
Booklet
12
9
L-PAM; Influence of Dose Intensity and Duration of Treatment on Toxicity and Therapeutic Response,
March
Booklet
12
10
cis-Platinum; Influence of Dose Intensity and Duration of Treatment on Toxicity and Therapeutic Response,
March
Booklet
12
11
6-Mercaptopurine; Influence of Dose Intensity and Duration of Treatment on Toxicity and Therapeutic Response / AND / Multiarmed Trials Showing the Superiority of Simultaneous Combinations of ARA-C + 6-MP Over Maximum Tolerated Single Drug Treatment (L1210 Leukemia),
April
Booklet
12
12
Combinations of ARA-C + 6-Thioguanine; Influence of the Relative Dose Intensity of Each Drug in The Combination and the Average RDI on the Therapeutic Response of Animals Bearing Different Burdens of Leukemia Cells,
May
Booklet
12
13
On Optimum Combination Chemotherapy Design. Does the Design of a Combination Make a Big Difference in the End-Results Achivable in Moderately and Very Advanced Experimental Leukemia?,
June
Booklet
12
14
Comparison of the Response of MAM 16/C Tumors in Mice and Breast Cancer in Women--To the Same 3-Drug Combination (CAF), Using the Same Dose Intensity Unit and the Same Normalization Standards,
June
Booklet
12
15
Some Thoughts on Combination Chemotherapy Designs for Treatment of Metastatic Breast Cancer in Women (Retrospective Interpretations of Observed Results and Proespective Planning),
July
Booklet
13
16
Still Another Look at the Influence of Dose and Schedule Variables on Toxicity and Therapeutic Response of Experimental Neoplasms (ARA-C and A Slow Release Form of ARA-C_,
July
Booklet
13
17
Cyclophosphamide; Importance of Dose Intensity Independent of Total Dose with Respect to Both Toxicity and Thereapeutic Response of Experimental Leukemias,
August
Booklet
13
18
Methotrexate; Effects of Treatment Variables (Including Dose Intensity and Total Dose) on Toxicity and the Therapeutic Response of Animals Bearing Different Burdens of Leukemia Cells,
August
Booklet
13
19
Adriamycin; Effects of Treatment Variables (Including Dose Intensity and Total Dose) on Toxicity and the Therapeutic Response of Animals Bearing P388 and L1210 Leukemia,
August
Booklet
13
20
6-Thioguanine; Effects of Treatment Variables (Including Dose Intensity and Total Dose) on Toxicity and the Therapeutic Response of Animals Bearing Different Burdens of Leukemia Cells,
September
Booklet
13
21
6-Mercaptopurine; Effects of Treatment Variables on Toxicity and the Therapeutic Response / AND / Combination Trials in Which the Dose Intensities of ARA- + 6-MP Were Varied in a Systematic Manner,
September
Booklet
13
22
Vincristine; Effects of Treatment Variables (Including Dose Intensity and Total Dose) on Toxicity and the Therapeutic Response of Animals Bearing Different Burdens of Leukemia Cells,
September
Booklet
13
23
ARA-C, Amethopterin, Vincristine and Vinblastine; Effects of Manipulating Dose and Schedule Variables on the Survival of AK Lymphoma and Normal Hematopoietic Colony-Forming Cells in the Marrow. (Data of Bruce, Meeker, Powers, and Valeriote, JNCI 42, 1969),
October
Booklet
13
24
L-PAM; Effect of Dose and Schedule Variables (Including Dose Intensity and Total Dose) on Lethal Toxicity and the Therapeutic Response in Animals Bearing Different Burdens of L1210 and P388 Leukemia Cells and Solid Ros Tumors,
October
Booklet
13
25
What Should We Expect on Manipulating the Dose and Schedule of a Given Drug in Different Ways when Treatin Experimental Neoplasms with Significantly Different Growth Rates?,
November
Booklet
13
26
Some Principles Which Seem Important in the Design of Chemotherapy to be Used Along or in an Adjuvant Setting,
November
Booklet
13
27
A Brief Summary of Experience on Treating Animals Bearing Responsive, Moderately Refractory, and Very Refractory Solid Tumors with Different Classes of Drugs and Two-Drug Combinations Delivered in Different Ways /AND/ Detailed Analyses of Some Multiarmed Combination Chemotherapy Trials Carried Out in a Responsive Tumor System (Ridgeway Osteogenic Sarcoma),
December
Booklet
1988
13
1
Summaries of Data Examined in Booklets Written in 1987,
January
Booklet
13
2
On Design of Combination Chemotherapy Regimens to be Used Alone or in an Adjuvant Setting,
January
Booklet
13
3
MAM 16/C Treatment with Cyclophosphamide, Adriamycin, and 5-FU Given Singly and in Combinations Delivered in Different Ways; Effect of Manipulating Dose and Schedule Variables on Toxicity and the Degree and Duration of Tumor Response,
February
Booklet
13
4
Analyses and Interpretations of the Influence of Dose and Schedule Variables with an S-Phase Specific Drug (ARA-C) on (1) Toxicity, and (2) The Degree and Duration of Response and Cure Rate of Animals Bearing Known Burdens of L1210 Leukemia Cells,
March
Booklet
13
5
Why Are the Effects of Manipulating the Dose and Schedule of PALMO-ARA-C on Toxicity and the Response of Animals Bearing L1210 Leukemia Quite Different From Those Observed With ARA-C?,
March
Booklet
13
6
Methotrexate (An S-Phase Specific Drug); Effects of Manipulating the Dose and Schedule and, in Turn, C With t on Toxicity and the Degree and Duration of Response of Murine Leukemias,
April
Booklet
13
7
MAM 16/C; Response of Animals Bearing Measurable Tumors (And Associated Metastatic Disease) to Surgery Only, Chemotherapy Only, and to Surgery + Chemotherapy,
May
Booklet
13
8
MAM 16/C (Trial 1489-K1); A Look at the Raw Data in 11 Arms of a Combination Modality Trial with Tabular and Plotted Compilations, Comparisons, and Interpretations. [Surgery, CAF, and Surgery Followed at Different Periods By CAF Given at Different Dose Intensities],
May
Booklet
13
9
MAM 16/C (Trial 1724-E1); Tabulations, Plots and Interpretations of Data Observed in 32 Arms of a Large Combination Modality Trial; Comparisons of the Effectiveness of Surgery Alone, Adiamycin and CAF Alone, and Surgery Plus Adiamycin or CAF Delivered in Different Ways,
June
Booklet
13
10
Mammary Adenocarcinoma 16/C; Detailed Analyses of Randomized Multiarmed Trials in Which Similarly Staged Animals Were Treated as Follows: Surgery Only, Adriamycin Only, and Surgery Plus Adriamycin Delivered in Different Ways,
June
Booklet
14
11
L1210 Leukemia; Treatment at Different Stages of Advancement with Cyclophosphamide Delivered in Different Ways; Effects of Dose Intensity, Duration of Treatment, and Total Dose on the Surviving Leukemia Cell Burden at the End of Treatment, the Cure Rate, and the Survival Time of Treatment Failures,
July
Booklet
14
12
L1210 Leukemia; Treatment With BCNU Delivered in Different Ways; Effects of Dose Intensity, Duration of Treatment, and Total Dose on the Degree and Duration of Therapeutic Response,
July
Booklet
14
13
A Continuing Study of the Effects of the Individual Dose Level, Dose Intensity, and Total Dose of Different Drugs on the Degree and Duration of Response of Experimental Neoplasms (CCNU and Methyl-CCNU),
August
Booklet
14
14
A Continuing Study of the Effects of Schedule , Dose Intensity, Duration of Treatment, and Total Dose on the Degree and Duration of Response of Experimental Neoplasms (Arabino-Sylcytosine, an S-Phase Specific Drug),
August
Booklet
14
15
A Progress Report on Retrospective Analyses of Experimental Toxicity and Therapeutic Trial Results, Focusing on This Question: To What Extent Does Dose Intensity Correlate with the Therapeutic Outcome, Independently of Total Dose?,
August
Booklet
14
16
cis-Platinum, L-PAM, and Cyclophosphamide; Effects of Dose Intensity, Duration of Treatment, and Total Dose on the Degree and Duration of Response of Animals Bearing Different Burdens of L1210 and P388 Leukemia Cells,
August
Booklet
14
17
Some Thoughts on the Influence of Dose and Schedule Manipulation on the Degree and Duration of Repsonse of Neoplasms with Widely Different Growth Rates,
September
Booklet
14
18
To What Extent Does the Dose Intensity of Anticancer Drugs Correlate with Therapeutic Outcome in Experimental Cancers--Independently of Total Dose,
October
Booklet
14
19
Why do Different Experimental Neoplasms with Different Growth Rates Respond so Differently wto Similar Dosages of a Given Drug?,
November
Booklet
14
20
Why Do Different Cancers with Different Growth Rates and Patterns Respond so Differently to Different Drugs and Combinations of Drugs When Delivered in the Same and Different Ways,
December
Booklet
1989
14
1
A Listing of Informal Reports to the Division of Cancer Treatment, National Cancer Institute (1974-1988),
January
Booklet
14
2
Tumor Differences, Drug Differences, Treatment Differences, and Effects on Therapeutic Outcome (Degree and Duration of Therapeutic Response),
January
Booklet
14
3
A Reproduction of and Old Review of the "Good and Very Poor Responses" of Many Transplantable Experimental Cancers to Drugs Available in the Early 1960's (Written 22 Years Ago),
March
Booklet
14
4
Tumor Differences, Drug Differences, Treatment Design Differences, and Effects on Therapeutic Outcome (Results Observed in the Lewis Lung Carcinoma System and Some Comparisons with Other Experimental Cancers),
March
Booklet
14
5
A Reproduction of and Old Report (1974) Having to do with the Dosage of Anticancer Drugs and Lethal Toxicity With Time (BDF1 Mice),
April
Booklet
14
6
A Look at the Shapes, Slopes, and Median Durations of Survival Curves of Children with Acute Lymphocytic Leukemia who were Treated in Different Ways--Compared with those of Variously Staged and Treated Leukemic Animals (Including Untreated Controls),
May
Booklet
14
7
Dose Intensity Versus Total Dose of Chemotherapy: Experimental Basis,
May
Booklet
14
8
What Might We Expect When Animals or Humans Bearing Different Cancers with Widely Different Growth and Regrowth Rates Are Treated with the same Drug or Drugs Delivered in the Same and Different Ways?,
June
Booklet
14
9
What Phenomena Affect the Shapes and Slopes of Dose-Response Curves, Time-Action Curvers, Tumor-Mass-Behavior Curves, Remission-Duration Curves, and Host-Survival Curves?,
September
Booklet
14
10
What Phenomena Affect the Shapes and Slopes of Survival Curves for Cancer-Bearing Animals Treated by Means of Surgery, Chemotherapy, and Surgery Plus Chemotherapy,
November
Booklet
Other manuscripts by Howard Earle Skipper
13
Experimental Evaluation of Potential Anticancer Agents. XIII. on the Criteria and Kinetics Associated with "Curability" of Experimental Leukemias,
February, 1964
Cancer Chemotherapy Reports
4
Successes and Failures at the Preclinical Level: Where Now? Howard E. Skipper,
[ca. 1972]
James Arly Nelson's collection assorted manuscripts
15
A Manual on Quantitative Drug Evaluation in Experimental Tumor Systems,
April 1962
Cancer Chemotherapy Reports
15
A Critical Evaluation of Cancer Chemotherapy,
April 1969
Symposium
15
The Biochemical Basics for the Drug Actions of Purines. By John A. Montgomery.,
Misc (Progress in Drug research)
15
The Relationship of the Metabolism of Anticancer Agents to Their Activity. By John A. Montgomery and Robert F. Struck, 1970
Misc (Progress in Medicinal Chemistry)
15
Cancer Chemotherapy Reports Volume 55 Number 4,
November 19741
15
LD10 Summary: Toxicity Testing of Anticancer Drugs in Small Experimental Animals Total Experience May 16, 1960-August 23, 1980,
1980
15
Experimental Chemotherapy and Tumor Cell Kinetics: Overview of Experimental Tumor Systems. By F.M. Schabel, W.R. Laster, and W.C. Rose. Unbound print of article. It appears to be prepublication,
May 1977
15
Tumor Growth and Drug Treatment of Cancer. By F.M. Schabel and L. Simpson-Herren. Unbound print of article. Prepared fro publication in Clinical Chemotherapy, Volume 3,
15
Increasing Therapeutic Response Rates to Anticancer Drugs by Applying the Basic Principles of Pharmacology. By F.M. Schabel et al (included handwritten note from Schabel taped to top page). From Pharmac. Ther. Vol 20, 1983
15
Concepts for Systemic Treatment of Micrometastases. By F.M. Schabel; reprint from Cancer vol 35,
January 1975
15
Program for Texas Anticancer Drug Development Consortium Meeting,
November 1986
Program
15
Drug Treatment of Malignant Tumors of Man and Animals--A Rational Approach to Cancer Chemotherapy. By Schabel.,
March 1969
Reprint
15
Animal Models as Predictive Systems. By Schabel., 1975
Reprint
15
Test Systems for Evaluating the Antitumor Activity of Nucleoside Analogues. By Schabel., 1979
Reprint
15
Synergism and Antagonism Among Antitumor Agents. By Schabel., 1975
Reprint
Jammes Arly Nelson correspondence
15
Readers report on Nelson's Ms. "Role of the Host in the Variable Chemotherapeutic Response of Advanced Ridgway Osteogenic Sarcoma" from Frank Schabel,
February 1982
Letter
15
Letter from J. Arley Nelson to Archie Bleyer and Francis Ali-Osman. Thank you note for forwarding of a resume to him,
April 1993
Letter